{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:23:35Z","timestamp":1740144215418,"version":"3.37.3"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"49","license":[{"start":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T00:00:00Z","timestamp":1607040000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>The neoadjuvant chemotherapy (NAC) is the gold standard initial treatment of the locally advanced breast cancer (LABC). However, the reliability of methods that used to assess response the NAC is still controversial. In this study, patients with LABC who underwent NAC were evaluated retrospectively. The assessment of response to NAC and the effect of axillary approach were investigated on LABC course.<\/jats:p>\n            <jats:p>The study comprised 94 patients who received NAC with an LABC diagnosis between 2008 and 2020. In our center, magnetic resonance imaging, ultrasonography, and <jats:sup>18<\/jats:sup> F-flouro deoxyglucose positron emission tomography\/computed tomography, and, for some patients, fine-needle aspiration biopsy of suspicious axillary lymph nodes have been performed to assess the effects of NAC. Patients with positive hormone receptor status received adjuvant hormonotherapy, and those with human epidermal growth factor receptor 2 gene expression were treated with trastuzumab. Adjuvant radiotherapy was applied to all patients undergoing breast conserving surgery. Radiotherapy was applied to the peripheral lymphatic areas in the clinical N1 to N3 cases regardless of the response to NAC.<\/jats:p>\n            <jats:p>The clinical response to the NAC was found that partial in 59% and complete in 19% of the patients. However, 21.2% of the patients were unresponsive. The mean of lymph nodes that excised with the procedure of sentinel lymph node biopsy (SLNB) was 2.4 (range 1\u20137). In 22 of the 56 patients who underwent SLNB, axillary dissection (AD) was added to the procedure upon detection of metastasis in frozen section examinations. There was no difference between the SLNB and AD groups regarding overall survival (OS; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.472) or disease-free survival (DFS) rates (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a\n                                 <jats:italic toggle=\"yes\">=<\/jats:italic>\u200a.439). However, there were differences in the OS (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.05) and DFS (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a\n                                 <jats:italic toggle=\"yes\">=<\/jats:italic>\u200a.05) rates on the basis of the LABC histopathological subtypes.<\/jats:p>\n            <jats:p>The study found that a relationship between molecular subtypes and LABC survival. However, the post-NAC axillary approach had no effect on OS or DFS. Therefore, multiple imaging and interventional methods are needed for the evaluation of NAC response. In addition, morbidity can be avoided after AD by the use of SLNB in cN0 patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000023538","type":"journal-article","created":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T04:13:47Z","timestamp":1607055227000},"page":"e23538","source":"Crossref","is-referenced-by-count":2,"title":["Management of the axilla with sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer"],"prefix":"10.1097","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2217-6819","authenticated-orcid":false,"given":"Suleyman Ozkan","family":"Aksoy","sequence":"first","affiliation":[{"name":"Department of General Surgery"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali \u0130brahim","family":"Sevinc","sequence":"additional","affiliation":[{"name":"Department of General Surgery"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00fccahit","family":"\u00dcnal","sequence":"additional","affiliation":[{"name":"Department of General Surgery"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pinar","family":"Balci","sequence":"additional","affiliation":[{"name":"Department of Radiology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0130lknur Bilkay","family":"G\u00f6rkem","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merih Guray","family":"Durak","sequence":"additional","affiliation":[{"name":"Department of Pathology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ozden","family":"Ozer","sequence":"additional","affiliation":[{"name":"Department of Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Recep","family":"Beki\u015f","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Faculty of Medicine, Dokuz Eyl\u00fcl University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00fc\u015fra","family":"Emir","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Faculty of Medicine, Katip Celebi University, \u0130zmir, Turkey."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,12,4]]},"reference":[{"key":"R1-20230916","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/cncr.22789","article-title":"Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with oestrogen receptor-positive breast cancer","volume":"110","author":"Semiglazov","year":"2007","journal-title":"Cancer"},{"key":"R2-20230916","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1093\/annonc\/mds132","article-title":"Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM\/2006\u201303, a multicentre, randomized, phase-II study","volume":"23","author":"Alba","year":"2012","journal-title":"Ann Oncol"},{"key":"R3-20230916","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1200\/JCO.2005.05.188","article-title":"Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from national surgical adjuvant breast and bowel project protocol B-27","volume":"23","author":"Mamounas","year":"2005","journal-title":"J Clin Oncol"},{"key":"R4-20230916","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.acra.2009.01.026","article-title":"Breast cancer sentinel node identification and classification after neoadjuvant chemotherapy- systematic review and meta analysis","volume":"16","author":"Kelly","year":"2009","journal-title":"Acad Radiol"},{"key":"R5-20230916","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes","volume":"30","author":"Von Minckwitz","year":"2012","journal-title":"J Clin Oncol"},{"key":"R6-20230916","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"R7-20230916","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1200\/JCO.2010.31.4930","article-title":"Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups","volume":"29","author":"Untch","year":"2011","journal-title":"J Clin Oncol"},{"key":"R8-20230916","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/tbj.13116","article-title":"Management of the axilla after neoadjuvant chemotherapy for breast cancer: sentinel node biopsy and radiotherapy considerations","volume":"24","author":"Currey","year":"2018","journal-title":"Breast J"},{"issue":"(Suppl 3)","key":"R9-20230916","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/j.ijrobp.2009.04.093","article-title":"Radiation d\u00f6\u015fe-volume effects in the heart","volume":"76","author":"Gagliarde","year":"2010","journal-title":"Radiat Oncol Biol Phys"},{"key":"R10-20230916","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","article-title":"Strategies for subtypes\u2013dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011","volume":"22","author":"Goldhirsch","year":"2011","journal-title":"Ann Oncol"},{"key":"R11-20230916","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1200\/JCO.2014.55.7827","article-title":"Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study","volume":"33","author":"Boileau","year":"2015","journal-title":"J Clin Oncol"},{"key":"R12-20230916","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1245\/s10434-013-3118-z","article-title":"Imaging response and residual metastatic axillary lymph node disease after neoadjuvant chemotherapy for primary breast cancer","volume":"20","author":"Hieken","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"R13-20230916","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1245\/s10434-011-1919-5","article-title":"Accuracy of clinical examination, dynamic mammogram, ultrasound, and MRI in determining postneoadjuvant pathologic tumor response in operable breast cancer patients","volume":"18","author":"Croshaw","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"R14-20230916","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.clbc.2011.06.007","article-title":"Accuracy of breast magnetic resonance imaging in predicting pathologic response in patients treated with neoadjuvant chemotherapy","volume":"11","author":"De Los","year":"2011","journal-title":"Clin Breast Cancer"},{"key":"R15-20230916","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1245\/s10434-011-1919-5","article-title":"Accuracy of clinical examination, digital mammogram, ultrasound, and MRI in determining postneoadjuvant pathologic tumor response in operable breast cancer patients","volume":"18","author":"Croshaw","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"R16-20230916","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1245\/s10434-014-4357-3","article-title":"Prospective trial of breast MRI versus 2D and 3D ultrasound for evaluation of response to neoadjuvant chemotherapy","volume":"22","author":"Lee","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"R17-20230916","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.jamcollsurg.2017.08.027","article-title":"MRI and prediction ofpathologic complete response in the breast and axilla after neoadjuvant chemotherapy for breast cancer","volume":"225","author":"Weber","year":"2017","journal-title":"J Am Coll Surg"},{"key":"R18-20230916","first-page":"963","article-title":"Use of PET for monitoring cancer therapy and for predicting outcome","volume":"46","author":"Weber","year":"2009","journal-title":"J Nucl Med"},{"key":"R19-20230916","doi-asserted-by":"crossref","first-page":"5366","DOI":"10.1200\/JCO.2006.05.7406","article-title":"Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F] fluorodeoxyglucose positron emission tomography","volume":"24","author":"Rousseau","year":"2006","journal-title":"J Clin Oncol"},{"key":"R20-20230916","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1200\/JCO.2000.18.8.1689","article-title":"Positron emission tomography using [(18)F] fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer","volume":"18","author":"Schelling","year":"2000","journal-title":"J Clin Oncol"},{"key":"R21-20230916","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1200\/JCO.2000.18.8.1676","article-title":"Positron emission tomography using [(18)F] fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy","volume":"18","author":"Smith","year":"2000","journal-title":"J Clin Oncol"},{"key":"R22-20230916","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0959-8049(01)00379-3","article-title":"Evaluation of good clinical response to neoadjuvant chemotherapy in primary breast cancer using [18F]-fluorodeoxyglucose positron emission tomography","volume":"38","author":"Burcombe","year":"2002","journal-title":"Eur J Cancer"},{"key":"R23-20230916","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/annonc\/mdh345","article-title":"Predictive value of [18F] FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy","volume":"15","author":"Kim","year":"2004","journal-title":"Ann Oncol"},{"key":"R24-20230916","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1200\/JCO.1998.16.1.93","article-title":"Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute","volume":"16","author":"Bonadonna","year":"1998","journal-title":"J Clin Oncol"},{"key":"R25-20230916","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/cncr.10741","article-title":"Pathobiology of preoperative chemotherapy: findings from the national surgical adjuvant breast and bowel (NSABP) protocol B-18","volume":"95","author":"Fisher","year":"2002","journal-title":"Cancer"},{"key":"R26-20230916","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1245\/s10434-012-2484-2","article-title":"The role for sentinellymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer","volume":"19","author":"Alvarado","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"R27-20230916","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1200\/JCO.2008.18.3228","article-title":"Sentinel lymph node biopsyafter neoadjuvant chemotherapy for advanced breast cancer: results of ganglion sentinelle et chimiotherapie neoadjuvante, a French prospective multicentric study","volume":"27","author":"Classe","year":"2009","journal-title":"J Clin Oncol"},{"key":"R28-20230916","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1245\/s10434-007-9403-y","article-title":"Sentinel lymph node biopsyperformed after neoadjuvant chemotherapy is accurate in patients with documented node-positive breast cancer at presentation","volume":"14","author":"Newman","year":"2007","journal-title":"Ann Sug Oncol"},{"key":"R29-20230916","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1245\/ASO.2003.05.012","article-title":"Lymphatic mapping and sentinel lymphadenectomy after preoperative therapy for stage II and III breast cancer","volume":"10","author":"Balch","year":"2003","journal-title":"Ann Surg Oncol"},{"key":"R30-20230916","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","article-title":"Sentinel-lymph-nodebiopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study","volume":"14","author":"Kuehn","year":"2013","journal-title":"Lancet Oncol"},{"key":"R31-20230916","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1001\/jama.2013.278932","article-title":"Sentinel lymph nodesurgery after neoadjuvant chemotherapy in patients with nodepositive breast cancer: the ACOSOG Z1071 (alliance) clinical trial","volume":"310","author":"Boughey","year":"2013","journal-title":"JAMA"},{"key":"R32-20230916","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s10549-018-5004-7","article-title":"Sentinel lymph nodebiopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study","volume":"173","author":"Classe","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"R33-20230916","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/SLA.0000000000003075","article-title":"Diagnostic accuracy of different surgical procedures for axillary staging after neoadjuvant systemic therapy in node-positive breast cancer: a systematic review and meta-analysis","volume":"269","author":"Simons","year":"2019","journal-title":"Ann Surg"},{"key":"R34-20230916","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"R35-20230916","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1073\/pnas.191367098","article-title":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications","volume":"98","author":"Sorlie","year":"2001","journal-title":"Proc Natl Acad Sci"},{"key":"R36-20230916","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1200\/JCO.2015.65.2289","article-title":"Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American society of clinical oncology clinical practice guideline","volume":"34","author":"Harris","year":"2016","journal-title":"J Clin Oncol"},{"key":"R37-20230916","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1634\/theoncologist.2008-0230","article-title":"The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine","volume":"14","author":"Ross","year":"2009","journal-title":"Oncologist"},{"key":"R38-20230916","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4048\/jbc.2015.18.1.22","article-title":"Sentinel lymph node biopsy alone after neoadjuvant chemotherapy in patients with initial cytology-proven axillary node metastasis","volume":"18","author":"Kim","year":"2015","journal-title":"J Breast Cancer"},{"key":"R39-20230916","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.clbc.2016.02.009","article-title":"Feasibility and prognostic effect of sentinel lymph node biopsy after neoadjuvant chemotherapy in cytology-proven, node positive breast cancer","volume":"16","author":"Parks","year":"2016","journal-title":"Clin Breast Cancer"},{"key":"R40-20230916","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ejca.2017.04.012","article-title":"Factors predictive of locoregional recurrence following neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancer: an analysis of the EORTC 10994\/BIG 1-00 study","volume":"79","author":"Gillon","year":"2017","journal-title":"Eur J Cancer"},{"key":"R41-20230916","first-page":"535","article-title":"Impact of pathological complete response to neoadjuvant chemotherapy in invasive breast cancer according to molecular subtype","volume":"45","author":"Cirier","year":"2017","journal-title":"Gynecol Obstet Fertil Senol"},{"key":"R42-20230916","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s10549-005-9008-8","article-title":"High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer","volume":"94","author":"Abrial","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"R43-20230916","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s10549-010-1027-4","article-title":"Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features","volume":"124","author":"Montagna","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"R44-20230916","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.14694\/EdBook_AM.2015.35.e17","article-title":"Neoadjuvant therapy for breast cancer: controversies in clinical trial design and standard of care","author":"White","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"R45-20230916","doi-asserted-by":"crossref","first-page":"R129","DOI":"10.1186\/bcr3324","article-title":"Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the national comprehensive cancer network: a prospective cohort study","volume":"14","author":"Vaz-Luis","year":"2012","journal-title":"Breast Cancer Res"},{"key":"R46-20230916","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1200\/JCO.2011.35.0868","article-title":"Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31","volume":"29","author":"Perez","year":"2011","journal-title":"J Clin Oncol"},{"issue":"(Suppl 2)","key":"R47-20230916","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.breast.2015.07.008","article-title":"Clinical implica- tions of the intrinsic molecular subtypes of breast cancer","volume":"24","author":"Prat","year":"2015","journal-title":"Breast"},{"key":"R48-20230916","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1158\/1055-9965.EPI-15-0243","article-title":"Breast cancer mortality in African-American and non-Hispanic White women by molecular subtype and stage at diagnosis: a population-based study","volume":"24","author":"Tao","year":"2015","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R49-20230916","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s10552-016-0791-9","article-title":"Occurrence and outcome of de novo metastatic breast cancer by subtype in a large, diverse population","volume":"27","author":"Tao","year":"2016","journal-title":"Cancer Causes Control"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000023538","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T03:23:07Z","timestamp":1694834587000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000023538"}},"subtitle":["A single-center study"],"short-title":[],"issued":{"date-parts":[[2020,12,4]]},"references-count":49,"journal-issue":{"issue":"49","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000023538","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2020,12,4]]}}}